REX Peptide ETF Launches on Nasdaq: What the First Dedicated Peptide Equity Vehicle Signals About Sector Capital and Research-Supply Dynamics

Key takeaways

• REX Shares launched the REX Peptide ETF (ticker: PEPT) on Nasdaq on 14 October 2026, tracking the VettaFi Peptide Index, which spans 36 global constituents across therapeutics, manufacturing, nutraceuticals, and cosmeceuticals.
• The fund charges a 0.65% net expense ratio and is the first single-ticket equity vehicle to capture the peptide sector end to end, rather than routing exposure solely through Eli Lilly and Novo Nordisk.
• Index methodology deliberately excludes the grey-market research-chemical segment; all constituents must meet minimum market-cap and liquidity thresholds, meaning the fund's composition is a practical proxy for which parts of the peptide value chain have achieved investable scale.
• For procurement professionals, the index's four-segment structure provides a useful taxonomy of the supply chain and indicates where commercial-scale capacity is concentrated.

What launched and why it matters

REX Shares announced the launch of the REX Peptide ETF (Ticker: PEPT) on 14 October 2026, describing it as "a thematic ETF built to own the peptide economy end to end." It is REX's third thematic ETF, following the REX Drone ETF (DRNZ) and the REX AI Chipmaking ETF (CHIP).

The fund cleared EDGAR on 13 October 2026 at a net expense ratio of 0.65%, becoming a single equity vehicle built around the peptide drug boom. Most portfolios currently hold peptide exposure only through Eli Lilly and Novo Nordisk; in addition to those two names, PEPT holds the developers, manufacturers, and platforms behind them.

For research-procurement professionals, the significance of the launch lies less in its investment mechanics than in what the index's construction reveals about where the sector's commercial infrastructure actually sits.

Index architecture: a taxonomy of the peptide value chain

The ETF is based on the VettaFi Peptide Index, which tracks global companies positioned to advance the development, manufacturing, and commercial adoption of peptide-based products, spanning four segments: therapeutics and medicine, manufacturing and medical devices, nutraceuticals and supplements, and cosmeceuticals and skincare.

Constituents must have a minimum market capitalisation of $100 million and a three-month average daily traded value of at least $1 million. The methodology allocates at least 80% of index weight to pure-play companies deriving at least half of their revenue or R&D activity from peptides, with constituent caps limiting concentration; as of 30 September 2026, the index holds 36 constituents.

Holdings are weighted on free-float market capitalisation at each quarterly rebalance, with an 80% weight allocated to the core tranche and 20% to the diversified tranche, with individual constituents capped at a maximum of 12% in the core tranche and 5% in the diversified tranche.

The diversified tranche is instructive in its own right. For inclusion in that tranche, a constituent must either derive 10% to 49% of total revenue from the four segments, commit 10% to 49% of its R&D or clinical pipeline to peptide development, or generate less than 10% of total revenue from peptides while maintaining a top-three global market share in one of the four segments. That final criterion means large-scale contract development and manufacturing organisations (CDMOs) with dominant positions in solid-phase peptide synthesis can qualify even if their peptide revenue share remains below half — a deliberate acknowledgement of the infrastructure dimension of the sector.

The manufacturing dimension

The inclusion of a dedicated manufacturing segment reflects a structural shift in how the sector is understood by capital markets. GLP-1 active pharmaceutical ingredient (API) production requires specialist solid-phase peptide synthesis at commercial scale, and that capacity cannot be assembled quickly. Peptides are the body's own signalling molecules re-engineered into precise, scalable medicines — the technology behind today's GLP-1 treatments and a growing pipeline of therapies spanning metabolic disease, cardiovascular indications, oncology, and rare disease.

The index's explicit inclusion of manufacturers and medical device companies alongside therapeutics developers is notable, given the deal activity that has characterised the CDMO segment in 2026. Samsung Biologics' tender offer for Swiss peptide CDMO PolyPeptide Group — valued at approximately CHF 1.46 billion — reached 87.88% acceptance by the end of its main offer period on 12 October 2026, one day before the ETF cleared EDGAR, according to PolyPeptide's ad-hoc announcement. The convergence of a major CDMO consolidation and the launch of the first thematic equity vehicle covering the sector in the same 48-hour window illustrates the speed at which institutional framing of the peptide industry is evolving.

What the index does not capture

The index's eligibility criteria impose a hard floor on which parts of the peptide economy are represented. Research-chemical suppliers, compounding pharmacies, and grey-market vendors are excluded by definition: their market capitalisations either fall below the $100 million threshold or their revenue mix does not qualify under the pure-play or diversified criteria.

By country, US companies represent 52.9% of index weight as of September 2026, indicating that the publicly traded part of the peptide supply chain remains North American-dominated, even though a substantial proportion of raw peptide API production — including the intermediate and starting materials used by UK and European research suppliers — originates in China.

This geographic gap matters for procurement teams. The index's 36 constituents represent the regulated, exchange-listed stratum of a supply chain that extends well below the listed threshold into private Chinese API producers, specialist reconstitution reagent suppliers, and cold-chain logistics providers. Capital flowing into PEPT supports the listed layer; it does not directly finance the upstream API capacity that most UK research laboratories ultimately depend on for peptide reference standards and research-grade material.

The amylin-GLP-1 pipeline as context

The ETF launch comes as the broader GLP-1 pipeline continues to expand. Novo Nordisk has filed CagriSema — an amylin-GLP-1 combination — with the FDA seeking clearance for adults with obesity or overweight who do not have diabetes, with a decision expected by the end of the year; approval would make it the first amylin-GLP-1 combination available by prescription in the US. Eli Lilly has said it will start additional studies of its eloralintide-tirzepatide combination this year. A broader pipeline translates directly into sustained demand for peptide API capacity — which in turn supports the investment case that the VettaFi Peptide Index is built on.

Practical implications for research procurement

For UK laboratory procurement teams, the REX Peptide ETF is not a procurement tool — it is an intelligence signal. Three practical observations follow from its construction:

Segment-level supply-chain mapping. The index's four-segment taxonomy (therapeutics, manufacturing, nutraceuticals, cosmeceuticals) provides a defensible framework for categorising supplier relationships and assessing concentration risk across a procurement portfolio. Suppliers that fall within the manufacturing segment of the index are operating at commercial scale and are subject to the financial disclosure standards of listed entities, which facilitates due diligence.

CDMO consolidation is not reversing. The explicit inclusion of a manufacturing tranche, combined with the CDMO M&A activity of 2026, suggests that index providers and asset managers anticipate further consolidation rather than fragmentation. Procurement teams that have not reviewed their sole-source dependencies on CDMOs that are acquisition targets should consider doing so.

The grey market is outside the investable universe by design. The index's eligibility thresholds mean that none of the vendors supplying uncharacterised or research-use-only peptides to self-dosing individuals are represented. That structural absence is a useful reminder that the regulatory and safety risks associated with the grey-market segment are not priced into the listed market — they remain an entirely separate domain, with its own oversight challenges, as recent adverse-event reporting has underscored.

The REX Peptide ETF (PEPT) is listed on Nasdaq. Index methodology is documented at VettaFi and the fund prospectus is filed with the SEC. This article does not constitute investment advice. BSR Intelligence covers the peptide research sector for procurement and compliance professionals in UK laboratories.